CN112996795B - 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 - Google Patents
作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 Download PDFInfo
- Publication number
- CN112996795B CN112996795B CN201980074211.0A CN201980074211A CN112996795B CN 112996795 B CN112996795 B CN 112996795B CN 201980074211 A CN201980074211 A CN 201980074211A CN 112996795 B CN112996795 B CN 112996795B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733061P | 2018-09-18 | 2018-09-18 | |
| US62/733,061 | 2018-09-18 | ||
| US201862749655P | 2018-10-23 | 2018-10-23 | |
| US62/749,655 | 2018-10-23 | ||
| US201962810911P | 2019-02-26 | 2019-02-26 | |
| US62/810,911 | 2019-02-26 | ||
| US201962883120P | 2019-08-06 | 2019-08-06 | |
| US201962883121P | 2019-08-06 | 2019-08-06 | |
| US62/883,121 | 2019-08-06 | ||
| US62/883,120 | 2019-08-06 | ||
| PCT/US2019/051592 WO2020061103A1 (en) | 2018-09-18 | 2019-09-17 | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112996795A CN112996795A (zh) | 2021-06-18 |
| CN112996795B true CN112996795B (zh) | 2024-11-12 |
Family
ID=68084982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980074211.0A Active CN112996795B (zh) | 2018-09-18 | 2019-09-17 | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
| CN201980074583.3A Active CN113227103B (zh) | 2018-09-18 | 2019-09-17 | 作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980074583.3A Active CN113227103B (zh) | 2018-09-18 | 2019-09-17 | 作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US11459340B2 (enExample) |
| EP (2) | EP3853233A1 (enExample) |
| JP (2) | JP7337174B2 (enExample) |
| KR (2) | KR20210060555A (enExample) |
| CN (2) | CN112996795B (enExample) |
| AU (2) | AU2019344899B2 (enExample) |
| BR (1) | BR112021005082A2 (enExample) |
| CA (2) | CA3113233A1 (enExample) |
| CL (1) | CL2021000628A1 (enExample) |
| CO (1) | CO2021004436A2 (enExample) |
| CR (1) | CR20210175A (enExample) |
| DK (1) | DK3853234T3 (enExample) |
| ES (1) | ES3036496T3 (enExample) |
| FI (1) | FI3853234T3 (enExample) |
| MX (1) | MX2021003158A (enExample) |
| PH (1) | PH12021550604A1 (enExample) |
| PL (1) | PL3853234T3 (enExample) |
| PT (1) | PT3853234T (enExample) |
| SA (1) | SA521421505B1 (enExample) |
| SG (1) | SG11202102679QA (enExample) |
| TW (1) | TWI827677B (enExample) |
| WO (2) | WO2020061103A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| BR112020007058A2 (pt) * | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| CN117263942A (zh) | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| WO2020156243A1 (zh) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| WO2021043077A1 (zh) * | 2019-09-06 | 2021-03-11 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
| CN114502165A (zh) * | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
| PH12022551102A1 (en) | 2019-11-08 | 2023-11-20 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
| CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| WO2021259077A1 (zh) * | 2020-06-22 | 2021-12-30 | 四川科伦博泰生物医药股份有限公司 | 取代吡嗪类化合物，包含其的药物组合物及其用途 |
| CN116113418A (zh) * | 2020-08-25 | 2023-05-12 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物及其制备方法和用途 |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN117098537A (zh) * | 2020-12-11 | 2023-11-21 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| US20250195533A1 (en) * | 2020-12-11 | 2025-06-19 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| CN117120449A (zh) * | 2020-12-11 | 2023-11-24 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| KR20230152652A (ko) * | 2020-12-11 | 2023-11-03 | 에라스카, 아이엔씨. | 암 치료를 위한 병용 요법 |
| CN117083283A (zh) * | 2020-12-11 | 2023-11-17 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| EP4259147A4 (en) * | 2020-12-11 | 2024-10-23 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022133217A1 (en) * | 2020-12-18 | 2022-06-23 | Genzyme Corporation | Process for preparing shp2 inhibitors |
| CN116848121A (zh) * | 2020-12-18 | 2023-10-03 | 建新公司 | 制备shp2抑制剂的方法 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| WO2022206684A1 (zh) * | 2021-03-31 | 2022-10-06 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US20240299388A1 (en) * | 2021-06-24 | 2024-09-12 | Erasca, Inc. | Erk1/2 and shp2 inhibitors combination therapy |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| WO2022271919A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| WO2023282702A1 (ko) * | 2021-07-09 | 2023-01-12 | 주식회사 카나프테라퓨틱스 | Shp2 억제제 및 이의 용도 |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023044065A1 (en) * | 2021-09-17 | 2023-03-23 | Erasca, Inc. | Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy |
| TW202322809A (zh) * | 2021-10-06 | 2023-06-16 | 美商艾瑞斯卡公司 | 三取代雜芳基衍生物作為src同源-2磷酸酶抑制劑之用途 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US20260055121A1 (en) * | 2022-08-24 | 2026-02-26 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| TW202440128A (zh) * | 2023-01-06 | 2024-10-16 | 美商艾瑞斯卡公司 | Raf抑制劑及erk1/2及/或shp2抑制劑組合療法 |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Family Cites Families (383)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| JPS62135834A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135835A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135830A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62135832A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62136654A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS62136651A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| JPS62136650A (ja) | 1985-12-11 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62206545A (ja) | 1986-03-07 | 1987-09-11 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| GB8729614D0 (en) | 1987-12-18 | 1988-02-03 | Beecham Group Plc | Novel compounds |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5360459A (en) | 1991-05-13 | 1994-11-01 | The Lubrizol Corporation | Copper-containing organometallic complexes and concentrates and diesel fuels containing same |
| JPH05196976A (ja) | 1991-11-18 | 1993-08-06 | Toshiba Corp | 有機非線形光学材料 |
| JPH05181221A (ja) | 1991-12-27 | 1993-07-23 | Konica Corp | ハロゲン化銀写真感光材料 |
| GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
| FR2687932A1 (fr) | 1992-02-27 | 1993-09-03 | Oreal | Dispersion huile-dans-l'eau susceptible de former des films composites. |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AU3785597A (en) | 1996-08-14 | 1998-03-06 | Takeda Chemical Industries Ltd. | Cyclic urea compounds, their production and use as herbicides |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6117973A (en) | 1997-02-24 | 2000-09-12 | Georgia Tech Research Corp. | PNA monomers with electron donor or acceptor |
| FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP2000072695A (ja) | 1998-08-24 | 2000-03-07 | Sumitomo Pharmaceut Co Ltd | 環状化合物 |
| CA2374898C (en) | 1999-05-21 | 2009-12-08 | Biovitrum Ab | Pyrazinyl-piperazine compounds, their use and preparation |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| WO2001010842A2 (en) | 1999-08-04 | 2001-02-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| HUP0203514A3 (en) | 1999-09-28 | 2004-01-28 | Eisai Co Ltd | Quinuclidine compounds and drugs containing them and process for preparation the same |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| JP4548761B2 (ja) | 2000-06-15 | 2010-09-22 | 富士フイルムホールディングス株式会社 | 潤滑剤組成物 |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10032633A1 (de) | 2000-07-05 | 2002-01-17 | Bayer Ag | Verfahren zum Auffinden von Hemmstoffen der Protoporphyrinogen-Oxidase |
| JP2002122954A (ja) | 2000-08-08 | 2002-04-26 | Fuji Photo Film Co Ltd | 感光性ハロゲン化銀写真乳剤、これを含有するハロゲン化銀写真感光材料および感光性ハロゲン化銀写真乳剤の感度向上方法 |
| AU2001279955A1 (en) | 2000-08-18 | 2002-03-04 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
| US6963001B2 (en) | 2000-09-30 | 2005-11-08 | Henkel Corporation | Low shrinkage thermosetting resin compositions and methods of use therefor |
| WO2002028813A1 (en) | 2000-09-30 | 2002-04-11 | Loctite | Low shrinkage thermosetting resin compositions and methods of use therefor |
| AU2002213467A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Modulation of ccr4 function |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| SE0103646D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic chroman compounds |
| MXPA03006268A (es) | 2001-01-16 | 2003-09-22 | Astrazeneca Ab | Compuestos terapeuticos de cromano. |
| NZ535574A (en) | 2001-01-16 | 2006-07-28 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
| CN1659143A (zh) | 2001-03-01 | 2005-08-24 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的含氮杂芳基化合物 |
| DE60139510D1 (de) | 2001-04-06 | 2009-09-17 | Biocryst Pharm Inc | Biarylverbindungen als serinproteaseinhibitoren |
| WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
| WO2003003008A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Chemical libraries useful for drug discovery processes |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| RU2312861C2 (ru) | 2002-03-05 | 2007-12-20 | Мерк Фросст Кэнада Лтд. | Ингибиторы катепсин-цистеинпротеазы |
| EP1487850A2 (en) | 2002-03-15 | 2004-12-22 | Nuevolution A/S | A building block forming a c-c or a c-hetero atom bond upon reaction |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| AU2003265663A1 (en) | 2002-08-23 | 2004-03-11 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
| WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| GB0306430D0 (en) | 2003-03-20 | 2003-04-23 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalysts |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| US20070010529A1 (en) | 2003-05-19 | 2007-01-11 | Kanji Takahashi | Nitrogenous heterocyclic compounds and medical use thereof |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| JP4231379B2 (ja) | 2003-10-15 | 2009-02-25 | 富士フイルム株式会社 | 潤滑剤組成物 |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| DE10355066A1 (de) | 2003-11-25 | 2005-06-23 | Basf Ag | Verfahren zur asymmetrischen Synthese |
| US7632946B2 (en) | 2004-02-06 | 2009-12-15 | Abbott Laboratories | Naphthyridine-based antibacterial compositions |
| JP2005263787A (ja) | 2004-02-17 | 2005-09-29 | Ishihara Sangyo Kaisha Ltd | アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
| JP4790703B2 (ja) | 2004-04-07 | 2011-10-12 | 武田薬品工業株式会社 | 環式化合物 |
| EP1595888A1 (en) | 2004-05-11 | 2005-11-16 | Degussa AG | Cycloolefin phosphine ligands and their use in catalysis |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| GB0415879D0 (en) | 2004-07-15 | 2004-08-18 | Bp Chem Int Ltd | Polymerisation catalyst |
| GB0418022D0 (en) | 2004-08-12 | 2004-09-15 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalyst |
| WO2006028958A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| GB0420396D0 (en) | 2004-09-14 | 2004-10-13 | Bp Chem Int Ltd | Polyolefins |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| WO2006061094A1 (en) | 2004-12-11 | 2006-06-15 | Merck Patent Gmbh | Liquid crystal compounds, liquid crystal medium and liquid crystal display |
| WO2006077367A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflamation |
| JP4749000B2 (ja) | 2005-02-22 | 2011-08-17 | 富士フイルム株式会社 | グリース組成物 |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| EP1867704B1 (en) | 2005-03-15 | 2010-09-15 | FUJIFILM Corporation | Surface treatment method using disc-like compound, (lubricating) composition for surface treatment, and surface-treated article |
| US20060156481A1 (en) | 2005-03-22 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| WO2006105291A2 (en) | 2005-03-31 | 2006-10-05 | Third-Order Nanotechnologies, Inc. | Heterocyclical chromophore architectures with novel electronic acceptor systems |
| ATE524182T1 (de) | 2005-04-21 | 2011-09-15 | Merck Serono Sa | 2,3-substituierte pyrazinsulfonamide als crth2- hemmer |
| EP1874769B1 (de) | 2005-04-25 | 2011-09-14 | Merck Patent GmbH | Neuartige aza-heterozyklen als kinase-inhibitoren |
| WO2006119800A1 (en) | 2005-05-09 | 2006-11-16 | Technische Universität Braunschweig | Light emitting compound for electroluminescent applications |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ATE485269T1 (de) | 2005-06-27 | 2010-11-15 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden |
| AR056867A1 (es) | 2005-06-27 | 2007-10-31 | Bristol Myers Squibb Co | Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas. |
| WO2007011721A1 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| JP2007056213A (ja) | 2005-08-26 | 2007-03-08 | Fujifilm Corp | 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材 |
| WO2007045462A2 (de) | 2005-10-19 | 2007-04-26 | Grünenthal GmbH | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln |
| FR2892859B1 (fr) | 2005-10-27 | 2008-06-06 | Commissariat Energie Atomique | Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications |
| EP1962892A4 (en) | 2005-11-22 | 2011-10-12 | Univ South Florida | INHIBITION OF CELL PROLIFERATION |
| WO2007064869A2 (en) | 2005-12-01 | 2007-06-07 | Yale University | Catalysts for aryl sulfide synthesis and method of producing aryl sulfides |
| JP2008007634A (ja) | 2006-06-29 | 2008-01-17 | Fujifilm Corp | 潤滑剤組成物 |
| JP2010501570A (ja) | 2006-08-23 | 2010-01-21 | エックスティーエル バイオファーマシューティカルズ リミテッド | ４−チオ置換キノリンおよびナフチリジン化合物 |
| KR101436179B1 (ko) | 2006-09-02 | 2014-09-01 | 메르크 파텐트 게엠베하 | 반응성 메소젠의 배향을 위한 입자 빔 방법 |
| WO2008118626A2 (en) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibitors of jnk and methods for identifying inhibitors of jnk |
| US7956020B2 (en) | 2007-03-29 | 2011-06-07 | Fujifilm Corporation | Lubricant composition, mechanical element, and method for producing triazine derivatives |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| CA2691987C (en) | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| US8063165B2 (en) | 2007-06-18 | 2011-11-22 | Bridgestone Corporation | Functional polymers prepared with sulfur-containing initiators |
| JP2009013314A (ja) | 2007-07-06 | 2009-01-22 | Toyo Ink Mfg Co Ltd | 光硬化型インキ |
| HUE025137T2 (en) | 2007-08-21 | 2016-01-28 | Senomyx Inc | Compositions are bitter taste blocking (blocking) compounds |
| US8143276B2 (en) | 2007-08-22 | 2012-03-27 | Xtl Biopharmaceuticals Ltd. | 4-thio substituted quinoline and naphthyridine compounds |
| WO2009026720A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| WO2009030318A1 (de) | 2007-08-29 | 2009-03-12 | Merck Patent Gmbh | Flüssigkristallanzeige |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| ES2446932T3 (es) | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| BRPI0817897A2 (pt) | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| WO2009078813A1 (en) | 2007-12-19 | 2009-06-25 | Nanyang Technological University | Method of forming oseltamivir and derivatives thereof |
| EP2098226A1 (de) | 2008-03-06 | 2009-09-09 | Forschungsverbund Berlin e.V. | AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| WO2010012363A1 (en) | 2008-07-28 | 2010-02-04 | Merck Patent Gmbh | Liquid-crystal display |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| DE102009055829A1 (de) | 2008-12-22 | 2010-06-24 | Merck Patent Gmbh | Flüssigkristallanzeige |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| DE102010006691A1 (de) | 2009-02-06 | 2010-10-28 | Merck Patent Gmbh | Flüssigkristallines Medium und Flüssigkristallanzeige |
| WO2010094029A2 (en) | 2009-02-16 | 2010-08-19 | University Of South Florida | Asymmetric cyclopropanation with succinimidyl diazoacetate |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| JP2010217692A (ja) | 2009-03-18 | 2010-09-30 | Konica Minolta Holdings Inc | 表示素子 |
| AU2010231162B2 (en) | 2009-04-02 | 2014-12-11 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives |
| EP2414317A2 (en) | 2009-04-03 | 2012-02-08 | The Scripps Research Institute | Palladium-catalyzed ortho-fluorination |
| DE102010012900A1 (de) | 2009-04-23 | 2010-11-25 | Merck Patent Gmbh | Flüssigkristallanzeige |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| WO2011005355A1 (en) | 2009-05-07 | 2011-01-13 | Achaogen, Inc. | Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria |
| WO2010147969A2 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| EP2443118A1 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
| US20120245158A1 (en) | 2009-06-16 | 2012-09-27 | Xianhai Huang | Gamma secretase modulators |
| JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ |
| WO2010148422A1 (en) | 2009-06-25 | 2010-12-29 | Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for treating parasitic infestations |
| US20120149663A1 (en) | 2009-08-18 | 2012-06-14 | Georgetown University | Boronic acid compositions and methods related to cancer |
| WO2011026579A1 (en) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2292720A1 (en) | 2009-09-08 | 2011-03-09 | Merck Patent GmbH | Liquid-crystal display |
| WO2011056929A1 (en) | 2009-11-04 | 2011-05-12 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
| KR20110088098A (ko) | 2010-01-28 | 2011-08-03 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| JP2013519719A (ja) | 2010-02-18 | 2013-05-30 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） | トリアゾロ［４，５−ｂ］ピリジン誘導体 |
| CA2791738C (en) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Aryl imidazolyl compounds for the treatment of cancer |
| KR20110101444A (ko) | 2010-03-08 | 2011-09-16 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 포함하는 유기 발광 소자 |
| KR20110104765A (ko) | 2010-03-17 | 2011-09-23 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012020357A1 (en) | 2010-08-09 | 2012-02-16 | Advinus Therapeutics Ltd. | Acetamide compounds, their process and pharmaceutical application |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| WO2012022487A1 (de) | 2010-08-20 | 2012-02-23 | Grünenthal GmbH | Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors |
| WO2012049624A1 (en) | 2010-10-14 | 2012-04-19 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| WO2012056419A1 (en) | 2010-10-28 | 2012-05-03 | Basf Se | N-heterocyclic carbene complexes, their preparation and use |
| US20120108819A1 (en) | 2010-10-28 | 2012-05-03 | Basf Se | N-Heterocyclic Carbene Complexes, Their Preparation And Use |
| KR20120045905A (ko) | 2010-11-01 | 2012-05-09 | 한국화학연구원 | 헤테로고리 축합된 피리도 화합물 및 이의 제조방법 |
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| JP5992435B2 (ja) | 2010-12-21 | 2016-09-14 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 循環からの生体分子の除去剤 |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| JP5618815B2 (ja) | 2010-12-24 | 2014-11-05 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、並びに、この組成物を用いた感活性光線性又は感放射線性膜及びパターン形成方法 |
| TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| US9295754B2 (en) | 2011-02-24 | 2016-03-29 | Emory University | Noggin inhibitory compositions for ossification and methods related thereto |
| CN103502218B (zh) | 2011-03-04 | 2016-08-17 | 生命科技公司 | 用于缀合生物分子的化合物和方法 |
| DE102012003796A1 (de) | 2011-03-18 | 2012-09-20 | Merck Patent Gmbh | Flüssigkristallines Medium |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN106701104B (zh) | 2011-03-29 | 2021-02-26 | 默克专利股份有限公司 | 液晶介质 |
| US20140163229A1 (en) | 2011-04-07 | 2014-06-12 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
| EP2522369A1 (en) | 2011-05-09 | 2012-11-14 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| TR201906779T4 (tr) | 2011-05-12 | 2019-05-21 | Proteostasis Therapeutics Inc | Proteostaz regülatörleri. |
| EP2709666B1 (en) | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| JP5782836B2 (ja) | 2011-05-27 | 2015-09-24 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子材料、有機エレクトロルミネッセンス素子、表示装置、照明装置、並びに化合物 |
| HK1197066A1 (zh) | 2011-06-03 | 2015-01-02 | Massachusetts Institute Of Technology | Z選擇性關環複分解反應 |
| JP6301830B2 (ja) | 2011-06-28 | 2018-03-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 有機半導体としてのインダセノ誘導体 |
| EP2729550B1 (en) | 2011-07-07 | 2018-02-21 | Merck Patent GmbH | Liquid-crystalline medium |
| CN103649163A (zh) | 2011-07-08 | 2014-03-19 | 默克专利股份有限公司 | 共轭聚合物 |
| DK2753605T3 (da) | 2011-09-09 | 2019-06-17 | Lantheus Medical Imaging Inc | Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| EP2615083A1 (en) | 2012-01-10 | 2013-07-17 | Studiengesellschaft Kohle mbH | Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst |
| JP5814141B2 (ja) | 2012-01-23 | 2015-11-17 | ユー・ディー・シー アイルランド リミテッド | 合成法、その合成法を用いて合成された化合物および有機電界発光素子 |
| CN112029513B (zh) | 2012-02-22 | 2024-02-23 | 默克专利股份有限公司 | 液晶介质 |
| US9217050B2 (en) | 2012-04-03 | 2015-12-22 | 3M Innovative Properties Company | Crosslinkable composition comprising photobase generators |
| KR102062517B1 (ko) | 2012-04-20 | 2020-01-06 | 바이엘 크롭사이언스 악티엔게젤샤프트 | Ｎ-시클로알킬-ｎ-［（헤테로시클릴페닐）메틸렌］-（티오）카르복사미드 유도체 |
| FR2992317B1 (fr) | 2012-06-22 | 2016-05-13 | Diverchim | Procede de preparation de peptides chiraux |
| US8575283B1 (en) | 2012-06-28 | 2013-11-05 | Formosa Plastics Corporation, U.S.A. | Heterocyclic organic compounds as electron donors for polyolefin catalysts |
| WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| SI2894151T1 (sl) | 2012-09-04 | 2021-01-29 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
| WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| KR101677866B1 (ko) | 2012-10-29 | 2016-11-18 | 코니카 미놀타 가부시키가이샤 | 위상차 필름, 원편광판 및 화상 표시 장치 |
| CA2890948A1 (en) | 2012-11-16 | 2014-05-22 | Basf Se | Lubricant compositions comprising epoxide compounds to improve fluoropolymer seal compatibility |
| JP2016500076A (ja) * | 2012-11-20 | 2016-01-07 | プリンシピア バイオファーマ インコーポレイテッド | Ｊａｋ３阻害剤としてのアザインドール誘導体 |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| US20150297741A1 (en) | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| US10927139B2 (en) | 2012-11-22 | 2021-02-23 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| EP2931836B1 (en) | 2012-12-12 | 2020-03-18 | Merck Patent GmbH | Liquid-crystalline medium |
| JP6335428B2 (ja) | 2012-12-21 | 2018-05-30 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| WO2014106524A2 (de) | 2013-01-03 | 2014-07-10 | Merck Patent Gmbh | Materialien für elektronische vorrichtungen |
| JP6322587B2 (ja) | 2013-02-08 | 2018-05-09 | 株式会社Ｊｏｌｅｄ | 有機エレクトロルミネッセンス素子 |
| US20150376198A1 (en) | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| US9487472B2 (en) | 2013-02-26 | 2016-11-08 | President And Fellows Of Harvard College | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer |
| US9580400B2 (en) | 2013-02-26 | 2017-02-28 | Northeastern University | Cannabinergic nitrate esters and related analogs |
| US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
| US9290528B1 (en) | 2013-03-15 | 2016-03-22 | University Of Kentucky Research Foundation | Light-activated compounds |
| JP5902641B2 (ja) | 2013-03-27 | 2016-04-13 | 富士フイルム株式会社 | 光干渉顔料およびその製造方法 |
| JP2016520552A (ja) | 2013-04-05 | 2016-07-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Ｐｐａｒアゴニスト |
| US10069079B2 (en) | 2013-04-08 | 2018-09-04 | Merck Patent Gmbh | Organic electroluminescent device with thermally activated delayed fluorescence material |
| KR102177883B1 (ko) | 2013-04-08 | 2020-11-12 | 메르크 파텐트 게엠베하 | 유기 전계발광 디바이스 |
| CA2944198C (en) | 2013-04-26 | 2021-11-16 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2) |
| JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
| US9844535B2 (en) | 2013-07-03 | 2017-12-19 | Indiana University Research And Technology Corporation | SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors |
| WO2015003137A1 (en) | 2013-07-03 | 2015-01-08 | University Of Connecticut | Polymerization of diene monomers |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| KR102252761B1 (ko) | 2013-08-02 | 2021-05-18 | 메르크 파텐트 게엠베하 | 액정 매질 |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
| EP2857405A1 (en) | 2013-10-01 | 2015-04-08 | Studiengesellschaft Kohle mbH | Process for the trans-selective hydroboration of internal alkynes |
| US10329270B2 (en) | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| JP6088995B2 (ja) | 2013-10-24 | 2017-03-01 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6522313B2 (ja) | 2013-10-24 | 2019-05-29 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| KR101537860B1 (ko) | 2013-11-22 | 2015-07-20 | 롯데케미칼 주식회사 | 내감마선 성능이 향상된 폴리카보네이트 수지 조성물 및 이를 이용한 성형품 |
| JP6215674B2 (ja) | 2013-11-29 | 2017-10-18 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6309834B2 (ja) | 2013-12-11 | 2018-04-11 | 株式会社Adeka | 着色性組成物 |
| JP2015163671A (ja) | 2013-12-13 | 2015-09-10 | 株式会社Adeka | ラジカル重合性組成物 |
| KR20150070027A (ko) | 2013-12-16 | 2015-06-24 | 메르크 파텐트 게엠베하 | 액정 매질 |
| US10020455B2 (en) | 2014-01-07 | 2018-07-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate platinum and palladium complex emitters containing phenyl-pyrazole and its analogues |
| JP6510539B2 (ja) | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| KR20150091942A (ko) | 2014-02-04 | 2015-08-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| JP6313604B2 (ja) | 2014-02-05 | 2018-04-18 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、感活性光線性又は感放射線性膜、感活性光線性又は感放射線性膜を備えたマスクブランクス、パターン形成方法、及び電子デバイスの製造方法 |
| AU2015223049B2 (en) | 2014-02-27 | 2019-03-21 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| MX376163B (es) | 2014-05-13 | 2025-03-07 | Hoffmann La Roche | Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. |
| ES2824105T3 (es) | 2014-05-16 | 2021-05-11 | Olaplex Inc | Formulaciones y métodos de tratamiento de queratina |
| NZ726874A (en) | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
| JP6692759B2 (ja) | 2014-06-05 | 2020-05-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規キノリン誘導体及び神経変性疾患におけるそれらの使用 |
| WO2016010485A1 (en) | 2014-07-16 | 2016-01-21 | Agency For Science, Technology And Research | Donor-acceptor polymers |
| US9818959B2 (en) | 2014-07-29 | 2017-11-14 | Arizona Board of Regents on behlaf of Arizona State University | Metal-assisted delayed fluorescent emitters containing tridentate ligands |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
| KR102437253B1 (ko) | 2014-08-26 | 2022-08-26 | 이데미쓰 고산 가부시키가이샤 | 유기 일렉트로 루미네선스 소자 및 전자 기기 |
| US10205190B2 (en) | 2014-08-28 | 2019-02-12 | Samsung Electronics Co., Ltd. | Composite electrolyte including polymeric ionic liquid and inorganic particles and lithium battery including the same |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| CA2968884A1 (en) | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| KR102384224B1 (ko) | 2014-12-30 | 2022-04-08 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| WO2016145383A1 (en) | 2015-03-11 | 2016-09-15 | Board Of Regents, University Of Texas System | Mth1 inhibitors for treating disease |
| KR102434696B1 (ko) | 2015-03-13 | 2022-08-22 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| CN107709295B (zh) | 2015-05-07 | 2021-05-04 | 百时美施贵宝公司 | 作为RORγ调节剂的三环砜类 |
| US9458308B1 (en) | 2015-05-12 | 2016-10-04 | Lotte Chemical Corporation | Polycarbonate resin composition with increased gamma-radiation resistant property and molded article using the same |
| US9879039B2 (en) | 2015-06-03 | 2018-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues |
| WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| FR3037952B1 (fr) | 2015-06-24 | 2019-01-25 | Compagnie Generale Des Etablissements Michelin | Procede de synthese d'oximes aromatiques |
| EP3112440B1 (en) | 2015-07-02 | 2019-07-24 | Merck Patent GmbH | Liquid-crystal medium |
| JP6869947B2 (ja) | 2015-07-22 | 2021-05-12 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用 |
| GB201514018D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And United States Of America Asrepresented By The Sec Dep Of Health And Human Servic | Novel tricyclic compounds and their use in the treatment of cancer |
| GB201514015D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And Dept Of Health And Human Services | Novel pyridazinones and their use in the treatment of cancer |
| WO2017026516A1 (ja) | 2015-08-12 | 2017-02-16 | 持田製薬株式会社 | イソチアゾール誘導体 |
| EP3133078B1 (en) | 2015-08-18 | 2019-01-30 | Samsung Electronics Co., Ltd. | Organometallic compound and organic light-emitting device including the same |
| KR101796227B1 (ko) | 2015-08-21 | 2017-11-10 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10240085B2 (en) | 2015-08-27 | 2019-03-26 | Samsung Electronics Co., Ltd. | Thin film and organic light-emitting device including the same |
| KR102542465B1 (ko) | 2015-09-22 | 2023-06-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| SE541053C2 (sv) | 2015-09-30 | 2019-03-19 | Epiroc Rock Drills Ab | System och förfarande för borrplansgenerering, borrigg, datorprogram samt datorprogramprodukt |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤をスクリーニングするための方法 |
| EP3162875B1 (en) | 2015-10-30 | 2018-05-23 | Merck Patent GmbH | Polymerisable compounds and the use thereof in liquid-crystal displays |
| WO2017077280A1 (en) | 2015-11-02 | 2017-05-11 | Sonia Lain | Tetrahydroindazoles and medical uses thereof |
| KR102932353B1 (ko) | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| KR20170069342A (ko) | 2015-12-10 | 2017-06-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CN106892924B (zh) | 2015-12-17 | 2021-01-08 | 四川科伦博泰生物医药股份有限公司 | 短效苯并二氮*衍生物、其制备方法及其用途 |
| KR102579752B1 (ko) | 2015-12-22 | 2023-09-19 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR20170075118A (ko) | 2015-12-22 | 2017-07-03 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10336772B2 (en) | 2015-12-28 | 2019-07-02 | Samsung Electronics Co., Ltd. | Bicarbazole compound, material for organic light-emitting device including bicarbazole compound, and organic light-emitting device including bicarbazole compound |
| KR102419178B1 (ko) | 2015-12-29 | 2022-07-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102396293B1 (ko) | 2015-12-29 | 2022-05-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2017117239A1 (en) | 2015-12-30 | 2017-07-06 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
| KR20170082126A (ko) | 2016-01-05 | 2017-07-13 | 삼성전자주식회사 | 조성물, 상기 조성물을 포함한 박막 및 이를 포함한 유기 발광 소자 |
| KR102633852B1 (ko) | 2016-01-25 | 2024-02-07 | 삼성디스플레이 주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
| BR112017021277A2 (pt) | 2016-02-08 | 2018-06-26 | H Lundbeck As | Síntese de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina |
| KR102628850B1 (ko) | 2016-03-07 | 2024-01-25 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| WO2017156265A1 (en) | 2016-03-09 | 2017-09-14 | President And Fellows Of Harvard College | Direct palladium-catalyzed aromatic fluorination |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CN108780273B (zh) | 2016-03-31 | 2022-06-28 | Dnp精细化工股份有限公司 | 感光性着色树脂组合物、滤色器及其制造方法以及显示设备 |
| KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102642199B1 (ko) | 2016-04-07 | 2024-03-05 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| ES2863873T3 (es) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| KR102218333B1 (ko) * | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| KR102666178B1 (ko) | 2016-06-07 | 2024-05-14 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| JP2019518063A (ja) | 2016-06-20 | 2019-06-27 | クラ オンコロジー， インコーポレイテッド | Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置 |
| US20180002604A1 (en) | 2016-06-30 | 2018-01-04 | Merck Patent Gmbh | Liquid-crystalline medium |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| US11299673B2 (en) | 2016-08-12 | 2022-04-12 | Merck Patent Gmbh | Liquid-crystal medium |
| KR102721990B1 (ko) | 2016-08-16 | 2024-10-29 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CA3033142A1 (en) | 2016-08-19 | 2018-02-22 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| JP6589795B2 (ja) | 2016-09-27 | 2019-10-16 | 信越化学工業株式会社 | スルホニウム塩、レジスト組成物及びパターン形成方法 |
| JP7179735B2 (ja) | 2016-09-28 | 2022-11-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重合性液晶材料および重合された液晶膜 |
| WO2018062276A1 (ja) | 2016-09-29 | 2018-04-05 | 住友化学株式会社 | 発光素子 |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| WO2018071620A1 (en) | 2016-10-13 | 2018-04-19 | Bristol-Myers Squibb Company | Heterocyclic sulfones as ror gamma modulators |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| MX2019005384A (es) | 2016-11-09 | 2019-08-12 | Squibb Bristol Myers Co | Sulfonas triciclicas como moduladores del receptor huerfano relacionado con retinoide (ror) gamma. |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| JP2020507625A (ja) | 2017-02-07 | 2020-03-12 | オブリーク セラピューティクス アーベー | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
| MX389800B (es) | 2017-02-07 | 2025-03-20 | Oblique Therapeutics Ab | Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| KR102395784B1 (ko) | 2017-03-27 | 2022-05-10 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| KR102461719B1 (ko) | 2017-05-23 | 2022-11-01 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| WO2018230595A1 (ja) | 2017-06-14 | 2018-12-20 | 富士フイルム株式会社 | 組成物、膜、レンズ、固体撮像素子、化合物 |
| KR20180137311A (ko) | 2017-06-16 | 2018-12-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| US20200123115A1 (en) | 2017-06-26 | 2020-04-23 | Esteve Pharmaceuticals, S.A. | Compounds having multimodal activity against pain |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| GB201712110D0 (en) | 2017-07-27 | 2017-09-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | New compounds and uses |
| KR20190014187A (ko) | 2017-07-27 | 2019-02-12 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함하는 유기 발광 소자 |
| JP7346015B2 (ja) | 2017-09-06 | 2023-09-19 | 住友化学株式会社 | 発光素子 |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| JP7447002B2 (ja) | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| KR102526756B1 (ko) | 2017-09-29 | 2023-04-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| EP3688118B1 (en) | 2017-09-29 | 2021-05-19 | Merck Patent GmbH | Polymerisable compounds and the use thereof in liquid-crystal displays |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| KR102518722B1 (ko) | 2017-11-21 | 2023-04-07 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| CN111936484A (zh) | 2017-12-22 | 2020-11-13 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物 |
| US11572370B2 (en) | 2018-01-08 | 2023-02-07 | Biohaven Therapeutics Ltd. | CD16A binding agents and uses thereof |
| KR102595918B1 (ko) | 2018-01-18 | 2023-11-14 | 삼성디스플레이 주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 상기 유기 발광 소자를 포함한 유기 발광 장치 |
| CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
| CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
| US11498930B2 (en) | 2018-02-13 | 2022-11-15 | Blueray Therapeutics (Shanghai) Co., Ltd | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
| KR102824606B1 (ko) | 2018-02-13 | 2025-06-25 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 표시 장치 |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| MA52421A (fr) | 2018-03-02 | 2021-01-06 | Otsuka Pharma Co Ltd | Composés pharmaceutiques |
| US12520712B2 (en) | 2018-03-08 | 2026-01-06 | Samsung Display Co., Ltd. | Organic light-emitting device |
| US11004918B2 (en) | 2018-03-09 | 2021-05-11 | Samsung Display Co., Ltd. | Electronic apparatus |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| CN117263942A (zh) | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| CN108794485B (zh) | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 一类toll样受体调节剂、其药物组合物、制备方法与用途 |
| KR102611661B1 (ko) | 2018-05-02 | 2023-12-08 | 나비레 파르마, 인코퍼레이티드 | Ptpn11의 치환된 헤테로사이클릭 억제제 |
| CN110492006B (zh) | 2018-05-14 | 2020-06-12 | 江苏三月光电科技有限公司 | 一种基于含硼有机化合物的电致发光器件 |
| CN108840886A (zh) | 2018-06-22 | 2018-11-20 | 南京工业大学 | 一种铂配合物蓝光材料以及有机发光器件 |
| MA53395A (fr) | 2018-07-24 | 2021-06-02 | Otsuka Pharma Co Ltd | Composés hétérobicycliques pour inhiber l'activité de shp2 |
| CN108863982B (zh) | 2018-08-04 | 2022-02-01 | 南昌航空大学 | 一种吩噻嗪/吩恶嗪类化合物的有机电合成方法 |
| US11518770B2 (en) | 2018-08-06 | 2022-12-06 | Purdue Research Foundation | Sesquiterpenoid analogs |
| PL3833670T3 (pl) | 2018-08-10 | 2024-08-19 | Navire Pharma, Inc. | Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka |
| JP7337174B2 (ja) * | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| IL304526B2 (en) | 2018-09-29 | 2025-05-01 | Novartis Ag | Production of compounds and preparations for inhibiting the activity of SHP2 |
| EP3856345A1 (en) | 2018-09-29 | 2021-08-04 | Novartis AG | Process of manufacture of a compound for inhibiting the activity of shp2 |
| JP2022508651A (ja) | 2018-10-08 | 2022-01-19 | レヴォリューション・メディスンズ，インコーポレイテッド | 癌を処置するためのｓｈｐ２阻害剤組成物および方法 |
-
2019
- 2019-09-17 JP JP2021539487A patent/JP7337174B2/ja active Active
- 2019-09-17 TW TW108133442A patent/TWI827677B/zh active
- 2019-09-17 US US17/277,293 patent/US11459340B2/en active Active
- 2019-09-17 DK DK19779687.3T patent/DK3853234T3/da active
- 2019-09-17 CR CR20210175A patent/CR20210175A/es unknown
- 2019-09-17 AU AU2019344899A patent/AU2019344899B2/en active Active
- 2019-09-17 PT PT197796873T patent/PT3853234T/pt unknown
- 2019-09-17 EP EP19779686.5A patent/EP3853233A1/en not_active Withdrawn
- 2019-09-17 CA CA3113233A patent/CA3113233A1/en active Pending
- 2019-09-17 SG SG11202102679QA patent/SG11202102679QA/en unknown
- 2019-09-17 BR BR112021005082-5A patent/BR112021005082A2/pt unknown
- 2019-09-17 FI FIEP19779687.3T patent/FI3853234T3/fi active
- 2019-09-17 US US16/573,900 patent/US20200115389A1/en not_active Abandoned
- 2019-09-17 EP EP19779687.3A patent/EP3853234B1/en active Active
- 2019-09-17 CN CN201980074211.0A patent/CN112996795B/zh active Active
- 2019-09-17 AU AU2019344897A patent/AU2019344897B2/en active Active
- 2019-09-17 PL PL19779687.3T patent/PL3853234T3/pl unknown
- 2019-09-17 ES ES19779687T patent/ES3036496T3/es active Active
- 2019-09-17 CA CA3113234A patent/CA3113234A1/en active Pending
- 2019-09-17 WO PCT/US2019/051592 patent/WO2020061103A1/en not_active Ceased
- 2019-09-17 CN CN201980074583.3A patent/CN113227103B/zh active Active
- 2019-09-17 KR KR1020217011212A patent/KR20210060555A/ko active Pending
- 2019-09-17 KR KR1020217011213A patent/KR102834408B1/ko active Active
- 2019-09-17 JP JP2021539488A patent/JP7542538B2/ja active Active
- 2019-09-17 WO PCT/US2019/051590 patent/WO2020061101A1/en not_active Ceased
- 2019-09-17 MX MX2021003158A patent/MX2021003158A/es unknown
-
2020
- 2020-05-12 US US15/930,309 patent/US10894797B2/en active Active
- 2020-09-18 US US17/025,790 patent/US11518772B2/en active Active
- 2020-10-19 US US17/074,337 patent/US11034705B2/en active Active
-
2021
- 2021-03-15 CL CL2021000628A patent/CL2021000628A1/es unknown
- 2021-03-17 SA SA521421505A patent/SA521421505B1/ar unknown
- 2021-03-17 PH PH12021550604A patent/PH12021550604A1/en unknown
- 2021-04-09 CO CONC2021/0004436A patent/CO2021004436A2/es unknown
-
2022
- 2022-11-01 US US18/051,679 patent/US12264167B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113227103B (zh) | 作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物 | |
| WO2023284730A1 (en) | Alkylidene derivatives as kras inhibitors | |
| WO2023249970A1 (en) | Bifunctional compounds containing pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| CN119451967A (zh) | 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物的双功能化合物 | |
| CN119630651A (zh) | 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有经取代的嘧啶衍生物的双功能化合物 | |
| CN119790053A (zh) | 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物 | |
| CN116783205A (zh) | 用于通过泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的化合物 | |
| HK40064126A (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| HK40064126B (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| HK40058474A (en) | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors | |
| HK40058474B (en) | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors | |
| EA044940B1 (ru) | Производные конденсированного трициклического кольца в качестве ингибиторов фосфатазы с доменом гомологии src2 | |
| WO2026011344A1 (en) | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40064126 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: Delaware, USA Applicant after: Nican therapy Address before: Delaware, USA Applicant before: Nikan medical Co. Country or region before: U.S.A. |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Fu Jiping Inventor after: Lou Yan Inventor after: He Yigang Inventor before: J.Fu Inventor before: Y.Luo Inventor before: Y.He |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |